
usd may pm et
summari make diagnost product medic imag system surgic product
emphasi women health also make medic aesthet system
nm price-to-earnings oper ep
risk assess reflect particip
industri character rapid technolog chang new
industri standard new market entrant addit
compet number compani
significantli greater resourc product depth
includ ge siemen phillip fuji kodak toshiba
howev maintain healthi reput solid
market share breast imag gynecolog
fiscal year end sep ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
lift target
base multipl
ep estim
multipl equal averag
forward price-to-earnings ratio adjust fy sep
ep estim mar-q ep
vs equal estim
cc million slightli ahead
expect led global cc growth
breast health busi follow
cc growth diagnost exclud blood
deterior basi point
mar-q primarili declin gross
margin neg affect
sever one-tim item inventori
reserv scrap charg unfavor
wrote-down million asset
medic aesthet busi mar-q
respons neg trend compani
previous note /kevin huang cfa
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop manufactur supplier premium diagnost
product medic imag system surgic product emphasi women health
oper five segment diagnost total revenu year end septemb
breast health medic aesthet gyn surgic skelet health
sell servic product combin direct sale servic personnel network
independ distributor sale repres segment made total revenu
remain fy revenu came servic
offer wide rang diagnost product use primarili aid diagnosi human
diseas primari diagnost product includ holx aptima famili assay thinprep system
rapid fetal fibronectin test
breast health product includ broad portfolio breast imag relat product accessori
includ digit mammographi system computer-aid detect cad mammographi
minim invas breast biopsi devic breast biopsi site marker breast biopsi guidanc system
holx advanc breast imag platform dimens util technolog call tomosynthesi
produc imag show multipl contigu slice imag breast
medic aesthet segment offer portfolio aesthet treatment system sculpsur
enabl plastic surgeon dermatologist medic practition perform non-invas
minim invas procedur remov hair treat vascular benign pigment lesion remov
multi-color tattoo revit skin reduc fat laser lipolysi reduc cellulit clear nail
infect toe fungu ablat sweat gland improv gynecolog health
gyn surgic segment make product aim toward gynecolog health novasur
endometri ablat system skelet health segment offer product bone densitomet
imag system use assist perform minim invas surgic procedur
competit landscap holx wide array product face competit varieti
competitor includ competitor even broader product portfolio great brand recognit
current environ manag care economically-motiv buyer consolid among
healthcar provid increas competit declin reimburs rate
increasingli requir compet basi price valu reliabl effici
impact major develop major develop fiscal although
compani made sever tuck-in acquisit latest major develop march
acquir cynosur inc develop manufactur supplier broad array light-bas
aesthet medic treatment system product use provid divers rang treatment
applic non-invas bodi contour hair remov tattoo remov skin revit
scar reduct well treatment vascular lesion cynosur busi refer
medic aesthet oper separ busi segment
januari divest blood screen busi grifol sale price
billion august acquir gen-prob lead maker molecular diagnost product
billion june acquir tct intern co ltd privat held distributor
medic product china acquisit tct provid establish nationwid sale
organ custom support infrastructur china
financi trend revenu grew billion fy sep billion prior year
five-year compound annual growth rate compound-annual-growth-rate adjust earn per share fy
vs fy five-year compound-annual-growth-rate adjust ep fy free cash flow defin
cash flow oper less capit expenditur million compar neg
million fy given net debt total capit ratio decemb expect
make larg acquisit near futur howev think opportunist tuck-in acquisit
like
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit lax
 food drug administr fda
mani product area histor
recession-resist equip use
non-elect procedur howev valuat
health care equip compani elev
rel
suggest posit fundament
reflect share think
higher valuat sub-industri mostli
warrant recent expand margin
robust revenu growth weaker sentiment
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-teen
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent year
success effort fda
reduc approv time medic devic
time see price pressur
incess headwind medic equip
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
howev us chines govern
seek lower health care cost provid
equip manufactur insul
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal howev decis could take
coupl year reach democrat
control hous repres
period think
see substanti effort republican
trump administr tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
hospit spend larg driver medic
equip sale robust
strong economi tax cut
job act tcja weaker growth
outlook economi roll-off
individu mandat think
hospit could see financi
pressur could pressur sale
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
revenu growth year-to-d march
 health equip index
appreci vs increas
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep hold opinion share inc
lift target base multipl
ep estim multipl equal
averag forward price-to-earnings ratio adjust fy sep ep estim
mar-q ep vs equal estim
sale rose constant currenc cc
million slightli ahead expect led global cc growth
breast health busi follow cc growth diagnost
basi point mar-q primarili declin gross
margin neg affect sever one-tim item
inventori reserv scrap charg unfavor foreign exchang movement
also wrote-down million asset medic aesthet busi
mar-q respons neg trend compani previous
lower target below-p
ep estim multipl close holx
five-year averag mar-q ep vs lower
estim sep ep estim remain unchang sale
increas million howev due signific churn holx
salesforc aggress forecast cynosur growth prospect took
million impair charg mar-q relat recent acquir
cynosur busi revenu growth guidanc reduc
posit note intern revenu grew organ
constant currenc basi diagnost revenu exclud divest blood
screen busi declin breast health grew gyn surgic
declin holx capit alloc strategi expect compani
focu tuck-in acquisit supplement exist busi /kevin
rais target line peer
fy sep ep estim set fy
dec-q ep vs ahead estim sale rose
organ growth yet oper margin fell bp gross
margin declin bp due sale blood screen busi
cost rose inclus cynosur medic aesthet
acquisit lift fy sep ep guidanc
lower effect tax rate fy /jeffrey
et cfra keep hold opinion share inc
maintain target ep
estim multipl near middl averag
ratio keep fy sep ep estim fy ep
dec-q ep vs higher estim
sale rose slightli ahead expect driven growth
breast health increas global molecular diagnost
posit view intern revenu growth constant
currenc domest sale rose less stellar gross margin narrow
basi point hurt less favor geograph product sale mix
posit view closur acquisit
strengthen posit breast-conserv surgeri see progress
breast health global molecular diagnost support
top-lin growth excess deploy support tuck-in acquisit
et cfra retain hold opinion share inc
maintain target
ep estim multipl near middl
averag ratio sep-q ep vs
lower estim lower fy sep ep
initi fy ep sep-q sale increas
constant currenc million difficult comparison
divestitur blood screen busi non-recurring royalti
revenu molecular diagnost breast health sale grew constant
medic aesthet declin cc gyn surgic grew
cc acquir cynosur busi continu headwind due
faxitron intend continu priorit
tuck-in acquisit capit alloc /kevin huang cfa
et cfra retain hold opinion share inc
rais target below-p
ep estim multipl near middl
five-year averag ratio jun-q ep vs
higher estim rais fy sep ep
lower fy ep jun-q sale increas
constant currenc million driven growth breast
health intern busi breast health sale grew
constant currenc intern busi grew exclud acquir
cynosur busi constant currenc august
announc departur cfo bob mcmahon agil result chief
account offic karleen oberton promot cfo also
announc acquisit faxitron leader digit specimen
radiographi million expect continu make tuck-in
acquisit like near futur /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
